Compare · FLAG vs GILD
FLAG vs GILD
Side-by-side comparison of First Light Acquisition Group Inc. (FLAG) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FLAG and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $161.66B, about 572.0x FLAG ($282.6M).
- Over the past year, FLAG is up 0.0% and GILD is up 13.7% - GILD leads by 13.7 points.
- GILD has hit the wire 6 times in the past 4 weeks while FLAG has been quiet.
- GILD has more recent analyst coverage (25 ratings vs 0 for FLAG).
- Company
- First Light Acquisition Group Inc.
- Gilead Sciences Inc.
- Price
- $27.42+268.55%
- $130.19-0.79%
- Market cap
- $282.6M
- $161.66B
- 1M return
- +0.00%
- +3.35%
- 1Y return
- +0.00%
- +13.68%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- 1992
- News (4w)
- 0
- 6
- Recent ratings
- 0
- 25
First Light Acquisition Group Inc.
First Light Acquisition Group, Inc. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is headquartered in Reston, Virginia.
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest FLAG
- SEC Form SC 13G/A filed by First Light Acquisition Group Inc. (Amendment)
- SEC Form SC 13G/A filed by First Light Acquisition Group Inc. (Amendment)
- SEC Form SC 13G/A filed by First Light Acquisition Group Inc. (Amendment)
- SEC Form SC 13G/A filed by First Light Acquisition Group Inc. (Amendment)
- First Light Acquisition Group Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- SEC Form 424B3 filed by First Light Acquisition Group Inc.
- SEC Form SC 13G/A filed by First Light Acquisition Group Inc. (Amendment)
- SEC Form SC 13G/A filed by First Light Acquisition Group Inc. (Amendment)
- First Light Acquisition Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure
- SEC Form S-1/A filed by First Light Acquisition Group Inc. (Amendment)
Latest GILD
- FDA Approval for VEKLURY issued to GILEAD SCIENCES INC
- CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
- Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
- Gilead Sciences downgraded by Leerink Partners with a new price target
- Chief Financial Officer Dickinson Andrew D sold $389,777 worth of shares (3,000 units at $129.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 168,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $389,758 worth of shares (3,000 units at $129.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 121,234 units (SEC Form 4)
- Gilead Sciences upgraded by HSBC Securities with a new price target
- Chairman & CEO O'Day Daniel Patrick sold $1,894,400 worth of shares (15,000 units at $126.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 607,133 units (SEC Form 4)
- U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market